Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Crohn's the third indication for Skyrizi after psoriasis and psoriatic arthritis, and a key step in AbbVie's aim to grow the drug – already one of its top sellers with sales of almost $3 billion ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

and Crohn’s disease (CD). Importantly, Skyrizi and Rinvoq have demonstrated compelling head-to-head data against several novel therapies in clinical studies, which have given them a competitive ...